To ensure the Cancer Moonshot goals and approaches were grounded in the best science, NCI convened a Blue Ribbon Panel of scientific experts as a working group to the National Cancer Advisory Board. In September of 2016, the Blue Ribbon Panel presented a final report outlining 10 research recommendations that represent areas that are well-positioned to accelerate progress in cancer prevention, diagnosis, treatment, and care.
The following research categories align with these 10 recommendations:
| Research Category | Amount1 |
|---|---|
| Network for Direct Patient Engagement | $14,637,947 |
| Cancer Immunotherapy Translational Science Network | $8,837,639 |
| Therapeutic Target Identification to Overcome Drug Resistance | $2,228,942 |
| A National Cancer Data Ecosystem for Sharing and Analysis | $21,434,446 |
| Fusion Oncoproteins in Childhood Cancers | $282,910 |
| Minimize Cancer Treatment’s Debilitating Side Effects | $3,679,370 |
| Prevention and Early Detection: Implementation of Evidence-Based Approaches | $11,907,567 |
| Retrospective Analysis of Biospecimens from Patients Treated with Standard of Care | $0 |
| Generation of Human Tumor Atlases | $12,881,852 |
| Development of New Enabling Cancer Technologies | $17,277,841 |
| Other Cancer Moonshot Priority Activities (e.g., Partnership for Accelerating Cancer Therapies) | $24,692,289 |
| Total | $117,860,803 |
| 1 Includes new obligations and recoveries from fiscal years 2017, 2018, 2019, 2020, 2021, 2022, and 2023 carryover accounts. | |